Clinical Network Services (UK) Ltd

Clinical Network Services (CNS) is an integrated service group focused on product development headquartered in Australia with offices in New Zealand, the UK, the Netherlands and the USA. CNS creates value for small-medium sized biotechnology companies by progressing early stage products through phase 1 & 2 clinical trials or the marketplace sooner. CNS offers a unique service where it integrates BioDesk, an intelligent global product development and regulatory affairs consultancy, with our committed, highly experienced Australian/New Zealand clinical operations and biometrics team. BioDesk’s expert consultants offer CMC/manufacturing, toxicology, clinical and regulatory affairs strategic advice and guide products efficiently through critical post-discovery development and into the clinic for the first time. With over 20 years’ experience on more than 950 projects, CNS is one of the most experienced providers within the market and a partner of choice for biotech companies. CNS’s small-medium size is considered a big advantage when relating to similar sized clients, though CNS takes a global development/ regulatory approach to ensure value is strategically added at every stage of the product development life cycle.

Company type
Paul Cronin
LinkedIn logo Director 

Karma Oncology

At Karma Oncology we are committed to helping our clients advance their oncology programs to the next stage. 

Pioneering early stage companies leverage our experienced panel of clinical development experts to develop best-in-class Clinical Development Plans to attract the right investors and optimise the clinical and regulatory strategy. 

Clinical stage companies come to us for our operational excellence and then stay with us for our industry leading quality and low-overhead pricing. We understand that experience, speed and excellent site relationships are the key to effective clinical study delivery.  And with Karma, you get the same team from start-to-finish, not only because we have among the lowest staff turnover in the business (<5% annually), but because we do not have a start up team and a monitoring team, it is all one team delivered by our career CRAs who provide continuity and expertise.

Our expertise is in solid tumours and haematological malignancies and spans a multitude of therapeutic approaches including autologous and CAR-T cell therapies. While oncology is in our name, we do also have experience in many other indications and our sister company, Karma Cardiology provides the same services for cardiology and cardiovascular disease.

Company type
Karen J. Williams
LinkedIn logo Chief Executive Officer